Poxvirus-based active immunotherapy synergizes with CTLA-4 blockade to increase survival in a murine tumor model by improving the magnitude and quality of cytotoxic T cells

@inproceedings{Foy2016PoxvirusbasedAI,
  title={Poxvirus-based active immunotherapy synergizes with CTLA-4 blockade to increase survival in a murine tumor model by improving the magnitude and quality of cytotoxic T cells},
  author={Susan P. Foy and Stefanie J. Mandl and Tracy B dela Cruz and Joseph J. Cote and Evan J. Gordon and E Johnson Trent and Alain Delcayre and James Bradley Breitmeyer and Alex Franzusoff and Ryan B. Rountree},
  booktitle={Cancer Immunology, Immunotherapy},
  year={2016}
}
The dramatic clinical benefit of immune checkpoint blockade for a fraction of cancer patients suggests the potential for further clinical benefit in a broader cancer patient population by combining immune checkpoint inhibitors with active immunotherapies. The anti-tumor efficacy of MVA-BN-HER2 poxvirus-based active immunotherapy alone or in combination with CTLA-4 checkpoint blockade was investigated in a therapeutic CT26-HER-2 lung metastasis mouse model. MVA-BN-HER2 immunotherapy… CONTINUE READING
BETA
5
Twitter Mentions

Citations

Publications citing this paper.
SHOWING 1-8 OF 8 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 41 REFERENCES

Elucidating immunologic mechanisms of PROSTVAC cancer immunotherapy

  • Journal for immunotherapy of cancer
  • 2014
VIEW 5 EXCERPTS
HIGHLY INFLUENTIAL

Induction of an antigen cascade by diversified subcutaneous/intratumoral vaccination is associated with antitumor responses.

  • Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2005
VIEW 4 EXCERPTS
HIGHLY INFLUENTIAL

Similar Papers

Loading similar papers…